Particulars (Rupees in Crores.) | Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 |
---|---|---|---|---|---|
Gross Sales | 8,408 | 7,867 | 7,012 | 6,315 | 5,971 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 8,408 | 7,867 | 7,012 | 6,315 | 5,971 |
Other Operating Income | 149 | 116 | 117 | 64 | 97 |
Other Income | 41 | 115 | 36 | 139 | 18 |
Total Income | 8,598 | 8,098 | 7,165 | 6,518 | 6,086 |
Total Expenditure | 5,800 | 5,498 | 5,014 | 4,504 | 4,165 |
PBIDT | 2,798 | 2,600 | 2,151 | 2,014 | 1,921 |
Interest | 196 | 274 | 226 | 201 | 285 |
PBDT | 2,602 | 2,326 | 1,925 | 1,813 | 1,636 |
Depreciation | 594 | 605 | 511 | 500 | 493 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 435 | 320 | 257 | 260 | 229 |
Deferred Tax | 160 | 194 | 199 | 158 | -14 |
Reported Profit After Tax | 1,413 | 1,207 | 958 | 895 | 928 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 1,413 | 1,207 | 958 | 895 | 928 |
Extra-ordinary Items | 0 | 61.72 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 1,413 | 1,145.28 | 958 | 895 | 928 |
EPS (Unit Curr.) | 41.76 | 35.67 | 28.3 | 52.91 | 54.82 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 520 | 440 | 280 | 500 | 400 |
Equity | 169.23 | 169.23 | 169.23 | 84.62 | 84.62 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 33.27 | 33.04 | 30.67 | 31.89 | 32.17 |
PBDTM(%) | 30.94 | 29.56 | 27.45 | 28.7 | 27.39 |
PATM(%) | 16.8 | 15.34 | 13.66 | 14.17 | 15.54 |
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.